Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week’s View, Dr. Eagle discusses the development and validation of the American Heart Association’s PREVENT risk assessment tool. He then explores implantable hemodynamic monitors and their role in improving survival in patients with heart failure and reduced ejection fraction. Finally, Dr. Eagle talks about the 10-year outcomes of the NOTION trial regarding transcatheter or surgical aortic valve implantation.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses recovery in peripartum cardiomyopathy. He then explores a systematic review and meta-analysis of the association of physical activity and cognitive decline among older adults. Finally, Dr. Eagle talks about the promises and perils of consumer mobile technologies in cardiovascular care.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses the use of non–Vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and weight. He then explores sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction. Finally, Dr. Eagle talks about polygenic risk in families with spontaneous coronary artery dissection.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses a JACC State of the Art Review noting direct oral anticoagulants (DOACs) should not be standard treatment. He then explores various ways of guiding intervention for complex coronary lesions by optical coherence tomography (OCT) or intravascular ultrasound (IVUS). Finally, Dr. Eagle talks about a prespecified analysis of the CLEAR Outcomes Randomized Trial on the impact of bempedoic acid on total cardiovascular events.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores rethinking “false positive” exercise ECG Tests in patients with microvascular dysfunction. He then discusses a recent comparison of direct oral anticoagulants vs Vitamin K antagonists after transcatheter mitral valve replacement. Finally, Dr. Eagle examines a post-hoc analysis of a randomized clinical trial assessing long-term clinical and echocardiographic outcomes following the Ross procedure.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores using AI Large Language Models for cardiology. He then discusses arterial thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. Finally, Dr. Eagle examines a focused update on the Advanced Cardiovascular Life Support Guidelines.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the breakthroughs, trends, and major developments in cardiology over the last twelve months.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the disparities in diagnosis, treatment, and outcomes of peripheral artery disease. He then discusses evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. Finally, Dr. Eagle examines the importance of residual leaks following percutaneous left atrial appendage occlusion and outcomes.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores longitudinal changes in pulmonary artery pressure late in life using data from the ARIC study. He then discusses the safety and tolerability of inclisiran for treatment of hypercholesterolemia. Finally, Dr. Eagle asses late gadolinium enhancement in hypertrophic cardiomyopathy and how it improves risk stratification based on current guidelines.  Subscribe to Eagle’s Eye View  

The podcast explores stroke and bleeding risk in patients with atrial fibrillation and a CHA2DS2-VASC risk score of 1. It discusses the key points in the recently released 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. The potential value of using high-sensitivity cardiac troponin as a biomarker to predict preeclampsia is also examined.